We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+44.51%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
Cap. Flow
+$2.7M
Cap. Flow %
0.77%
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.42M
2
NUVL
Nuvalent
NUVL
+$7.29M
3
BIIB icon
Biogen
BIIB
+$6.21M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.88M
5
TERN
Terns Pharmaceuticals
TERN
+$4.56M

Top Sells

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$10.8M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.26M
3
AKRO
Akero Therapeutics
AKRO
+$5.48M
4
COGT icon
Cogent Biosciences
COGT
+$5.3M
5
NKTX icon
Nkarta
NKTX
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 79.93%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
51
Seres Therapeutics
MCRB
$46.3M
$2.1M 0.6%
18,721
+396
+2% +$53.1K
COGT icon
52
Cogent Biosciences
COGT
$7.07B
$2.07M 0.59%
179,000
-427,608
-70% -$5.3M
IMGN
53
DELISTED
Immunogen Inc
IMGN
$2.02M 0.58%
407,269
-31,426
-7% -$170K
SDGR icon
54
Schrodinger
SDGR
$1.15B
$2.02M 0.58%
+108,000
New +$2.24M
ISEE
55
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.89M 0.54%
88,243
-89,121
-50% -$1.9M
ABOS icon
56
Acumen Pharmaceuticals
ABOS
$157M
$1.59M 0.46%
295,115
-124,885
-30% -$839K
LVTX
57
DELISTED
LAVA Therapeutics
LVTX
$1.53M 0.44%
437,762
-173,047
-28% -$794K
CTIC
58
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.53M 0.44%
254,361
-729,155
-74% -$3.98M
CLYM
59
Climb Bio
CLYM
$692M
$1.5M 0.43%
409,202
+7,114
+2% +$21.1K
TRVI icon
60
Trevi Therapeutics
TRVI
$2.61B
$1.48M 0.42%
767,631
-171,634
-18% -$338K
SGEN
61
DELISTED
Seagen Inc. Common Stock
SGEN
$1.42M 0.41%
11,016
+389
+4% +$50.2K
AMYT
62
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$1.41M 0.4%
192,995
+4,695
+2% +$33.1K
CMPX icon
63
Compass Therapeutics
CMPX
$349M
$1.35M 0.39%
268,307
+6,217
+2% +$24.8K
ATXS
64
DELISTED
Astria Therapeutics
ATXS
$1.21M 0.35%
+81,204
New +$837K
IMGN
65
CALL
DELISTED
Immunogen Inc
IMGN
$1.15M 0.33%
+232,000
New +$1.26M
NTLA icon
66
Intellia Therapeutics
NTLA
$1.55B
$1.14M 0.33%
32,770
+759
+2% +$36.1K
PHVS icon
67
Pharvaris
PHVS
$2.37B
$1.13M 0.32%
+100,000
New +$526K
JBIO
68
Jade Biosciences
JBIO
$1.22B
$1.08M 0.31%
+1,054
New +$765K
AVXL icon
69
CALL
Anavex Life Sciences
AVXL
$250M
$950K 0.27%
102,600
+2,600
+3% +$27.8K
VERU icon
70
PUT
Veru
VERU
$35.6M
$924K 0.26%
17,500
-37,500
-68% -$3.09M
CUE icon
71
Cue Biopharma
CUE
$128M
$873K 0.25%
+10,209
New +$934K
ALT icon
72
Altimmune
ALT
$580M
$831K 0.24%
50,546
-49,923
-50% -$561K
CYTK icon
73
Cytokinetics
CYTK
$10.9B
$802K 0.23%
+17,500
New +$753K
AXSM icon
74
Axsome Therapeutics
AXSM
$12.1B
$771K 0.22%
+10,000
New +$598K
STXS icon
75
Stereotaxis
STXS
$133M
$735K 0.21%
354,925
+8,694
+3% +$17K
1 2
3
4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management's Q4 2022 filing shows 29 new, 39 increased, 21 reduced and 18 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M. The largest sale was Veracyte, an estimated $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Technology.

  • Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
  • Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
  • Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
  • Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
  • Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.